Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

1.0K
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.0K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

826
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
826
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

952
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DIGIT-HF: Results From the Win Ratio Analyses.

Circulation. Heart failure·2026
Same author

Simple ECG features predict successful catheter ablation of idiopathic premature ventricular contractions with an inferior axis.

Journal of electrocardiology·2026
Same author

[Position paper of the German Society of Cardiology-quality criteria for performing catheter ablation of atrial fibrillation: executive summary].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same author

Ventricular conduction is a marker for arrhythmic risk in SCN5A-E1784K overlap sodium channel disease.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial.

European heart journal·2026
Same author

Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: the STOPSTORM.eu study.

European heart journal·2026

Related Experiment Video

Updated: May 2, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

16.8K

Risk stratification in electrical cardiomyopathies.

Christian Veltmann1, Rainer Schimpf, Martin Borggrefe

  • 11st Department of Medicine - Cardiology, University Medicine Mannheim, Mannheim, Germany. christian.veltmann@umm.de

Herz
|January 22, 2010
PubMed
Summary

Electrical cardiomyopathies, including LQTS and CPVT, increase syncope and sudden cardiac death risk, especially in young patients. Individual risk stratification using clinical, genetic, and demographic data is crucial for effective management.

More Related Videos

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.0K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

803

Related Experiment Videos

Last Updated: May 2, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

16.8K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.0K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

803

Area of Science:

  • Cardiology
  • Genetics
  • Electrophysiology

Background:

  • Electrical cardiomyopathies, such as Long QT Syndrome (LQTS), Short QT Syndrome (SQTS), Brugada syndrome, and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), are rare genetic disorders.
  • These conditions significantly elevate the risk of syncope and sudden cardiac death (SCD), predominantly affecting young individuals and children.
  • The lack of large prospective randomized studies necessitates reliance on retrospective data for risk stratification.

Purpose of the Study:

  • To outline the current understanding of risk stratification in patients with electrical cardiomyopathies.
  • To highlight the therapeutic strategies for different types of electrical cardiomyopathies.
  • To emphasize the importance of individualized risk assessment based on available data and guidelines.

Main Methods:

  • Review of retrospective data from single- and multicenter registries.
  • Analysis of clinical phenotype, including electrocardiogram (ECG) findings.
  • Inclusion of patient history (syncope, sudden cardiac arrest), demographic data (age, gender), and genetic information (genotype) for risk assessment.

Main Results:

  • The implantable cardioverter defibrillator (ICD) is the primary therapy for Brugada syndrome and SQTS due to the lack of proven pharmacological prevention of SCD.
  • Beta-blockers are the first-line treatment for LQTS and CPVT, with ICD indicated for high-risk individuals.
  • Clinical phenotype, syncope history, and demographic factors are key for risk stratification in all electrical cardiomyopathies; genotype is significant for LQTS and CPVT.

Conclusions:

  • Individualized risk stratification is paramount for managing patients with electrical cardiomyopathies.
  • Therapeutic approaches vary, with ICDs for some conditions and beta-blockers for others, guided by risk assessment.
  • Integrating clinical, demographic, and genetic data ensures optimal patient management and prevention of adverse outcomes.